Background Older patients with chronic hepatitis C have a lower virological response to interferon (IFN) treatment compared to younger patients. The efficacy of telaprevir (TVR) and PEG-IFN plus ribavirin combination therapy and the predictive value of recently identified IFN lambda (IFNL) 4 polymorphisms on the outcome of therapy for older patients have not been addressed. Methods We assessed predictive factors for sustained virological response (SVR) to triple therapy in 226 younger (B65 years) and 87 older ([65 years) Japanese patients with chronic genotype 1 hepatitis C. IFNL4 polymorphism ss469415590 was analyzed by Invader assay. Results The SVR rate for older patients was slightly lower than for younger patients (69 vs. 82 %, P = 0.043).
Introduction
Hepatitis C virus (HCV) infection affects more than 3 % of the world's population [1] and often causes cirrhosis and hepatocellular carcinoma (HCC) [2, 3] . To prevent the development of HCC and advanced liver disease, interferon (IFN)-based therapies are administered to patients with chronic HCV infection. The success of treatiang chronic HCV infection with pegylated IFN-alpha (PEG-IFN) and ribavirin (RBV) varies by HCV genotype, and HCV genotype 1 tends to be less responsive to PEG-IFN/ RBV.
Average patient age has been increasing in Japan [4] , and such older patients have a lower virological response with PEG-IFN/RBV treatment compared to younger patients [5] [6] [7] . Anemia and other adverse events also occur more frequently in older patients [8, 9] .
Recently telaprevir (TVR) has been approved for clinical use in several countries. Patients with high viral load of genotype 1 are treated with a three-drug combination therapy of TVR and PEG-IFN/RBV for 24 weeks. Since TVR is a selective inhibitor of HCV NS3/4A protease activity, marked improvement in sustained virological response (SVR) rates are expected [10] [11] [12] [13] [14] . Furusyo et al. [15] examined the efficacy of triple therapy among older Japanese patients, but the effects of TVR dose reduction on treatment response and adverse events for older patients are unknown.
Recent genome-wide association studies have shown that common single nucleotide polymorphisms (SNPs) rs8099917 and rs12979860 near the interleukin (IL)-28B gene on chromosome 19 are strongly associated with outcomes of both PEG-IFN plus RBV [16] [17] [18] [19] dual therapy and TVR, PEG-IFN and RBV triple therapy [20, 21] . More recently, a polymorphism (ss469415590) within the gene that encodes a novel interferon-lambda 4 (IFNL4) protein has been found to be more strongly associated with HCV clearance and outcome of PEG-IFN plus RBV combination treatment compared to rs12979860 [22] . This IFNL4 protein can be produced by individuals who carry the DG allele of the ss469415590 variant (IFNL4-DG) but not by individuals who are homozygous for the IFNL4-TT allele because of a frameshift in exon 1 caused by the insertion variant [22] . The rs12979860 variant is located within intron 1 of IFNL4. Linkage disequilibrium is strong between the IFNL4-DG allele and the unfavorable rs12979860-T allele in individuals of European or Asian ancestry, whereas this linkage disequilibrium is moderate in individuals of African ancestry. Compared to rs12979860, ss469415590 is more strongly associated with HCV clearance in individuals of African ancestry, although it provides comparable performance in Europeans and Asians.
In the present study, we assessed the efficacy of the IFNL4 polymorphism and the effect of TVR dose reduction on treatment response and adverse events in TVR, PEG-IFN plus RBV triple therapy in older Japanese patients.
Methods

Patients
A total of 313 patients with chronic genotype 1 HCV infection who were treated with TVR, PEG-IFNa2b, and RBV triple therapy between November 2011 and July 2013 at Hiroshima University Hospital and hospitals belonging to the Hiroshima Liver Study Group were enrolled. Inclusion criteria for the therapy included remaining positive for genotype 1 HCV RNA for 6 months and having an HCV RNA level C5.0 log IU/mL, as determined by the COBAS TaqMan HCV test (Roche Diagnostics KK). Patients with cirrhosis were excluded.
Patients were classified according to response to prior interferon therapy. Non-responders never became HCV RNA-negative during prior therapy, whereas relapsers became HCV RNA-negative before the end of treatment but reverted to being HCV RNA-positive after treatment was discontinued.
HCV RNA levels HCV RNA levels were measured using the TaqMan reverse transcription polymerase chain reaction (PCR) test. The linear dynamic range was 1.2-7.8 log IU/mL. Samples that exceeded the measurement range were diluted with phosphatebuffered saline and reanalyzed. Amino acid substitutions at position 70 in the HCV core protein (core70) were determined using direct sequencing of PCR products after extraction and reverse transcription of HCV RNA as in Akuta et al. [23, 24] .
Single-nucleotide polymorphism (SNP) genotyping
Each patient was genotyped for rs8099917 in the IL28B locus, ss469415590 in the IFNL4 locus, and rs1127354, an inosine triphosphate pyrophosphate (ITPA) SNP reported to be associated with ribavirin-induced anemia [25] [26] [27] . Samples were genotyped using the Illumina HumanHap610-Quad Genotyping BeadChip or with the Invader or TaqMan assays, as described previously [28, 29] .
Therapeutic protocol
In this study, 750 mg of TVR (Telavic; Mitsubishi Tanabe Pharma, Osaka, Japan) were administered 3 times a day at 8-h intervals after meals (2,250 mg/day) in 174 patients and twice per day (1,500 mg/day) in 139 patients. The TVR dose was determined by each physician according to age, sex, body weight, and hemoglobin level. PEG-IFNa2b (PEG-Intron, MSD, Tokyo, Japan) was injected subcutaneously at a median dose of 1.5 lg/kg once per week (50-150 lg/week). 200-600 mg of RBV (Rebetol, MSD) was administered after breakfast and dinner. The RBV dose was adjusted by body weight (600 mg for \60 kg; 800 mg for 60-80 kg; and 1,000 mg for [80 kg). Triple therapy with PEG-IFNa2b, RBV, and TVR was continued for 12 weeks and then switched to PEG-IFNa2b and RBV dual therapy for an additional 12 weeks. Completion of the treatment was defined as completion of both the 12 weeks of TVR and the 24 weeks of PEG-IFN/RBV treatment.
Efficacy of the treatment
Sustained virological response (SVR) was defined as undetectable serum HCV RNA at 24 weeks after the end of treatment. Rapid virological response (RVR) was defined as undetectable HCV RNA at week 4 of treatment.
Statistical analysis
Continuous variables are presented as median and range and were analyzed using the Mann-Whitney U-test. Categorical variables were compared using the Chi square or Fisher exact test, as appropriate. Multivariate analysis was conducted with a Cox proportional hazard model using the stepwise selection of variables or two logistic analyses. All statistical analyses were performed using the SPSS software package (version 12.0 for Windows, SPSS Inc., Chicago, IL, USA), with P \ 0.05 denoting statistical significance.
Results
Baseline patient characteristics
Patients are grouped according to age (younger: B65 years, n = 226; older: [65 years, n = 87) in Table 1 . As IFNL4 SNP ss469415590 is in strong linkage disequilibrium with IL28B SNPs rs8099917 and rs12979860 [22] , only 4 out of 313 patients (1.3 %) showed discrepant haplotypes in this study. In older patients, hemoglobin levels were lower and serum creatinine levels were higher than in younger patients. More older patients received a reduced initial dose of TVR (1,500 mg) compared to younger patients. The older group included 17 treatment-naïve patients, 40 prior relapsers, and 30 previous non-responders. The younger group included 96 treatment-naïve patients, 94 prior relapsers, and 63 previous non-responders (P = 0.138).
The initial average dosage of TVR based on weight was similar between older and younger patients (32.6 ± 0.97 vs. 32.0 ± 0.54 mg/kg); however, the initial PEG-IFNa2b dosage was significantly larger, and the RBV dosage was significantly smaller in older patients compared to younger patients (1.49 ± 0.02 vs. 1.46 ± 0.01 lg/kg, P = 0.04 and 10.1 ± 0.3 vs. 11.0 ± 0.14 mg/kg, P = 0.012, respectively).
Sustained virological response by age
Outcome of therapy could be determined for 154 out of the 226 younger patients and 58 out of the 87 older patients. The SVR rate for older patients was slightly lower than that for younger patients (69 vs. 82 %, P = 0.043) (Fig. 1) . 4 /lL, P = 0.012), completion of the treatment (OR 47.776 for discontinuation of the treatment, P = 0.013), and IL28B TT genotype (OR 71.693 for TG?GG genotypes, P = 0.002) ( Table 3) .
Effect of IFNL4 genotype and response to previous interferon treatment in older patients
We assessed the relationship between IFNL4 genotype and SVR in older patients. Patients with the ss469415590 TT/ TT genotype were significantly more likely to achieve SVR compared to those with the TT/DG or DG/DG genotypes (82 vs. 43 %, P = 0.012) ( Table 2 ). According to the response to previous IFN treatment, the SVR rate for treatment-naïve patients and prior relapsers with the ss469415590 TT/TT genotype was significantly higher than for prior nonresponders (92 vs. 56 %, P = 0.017) (Fig. 2a) .
Relationship of IFNL4 to SVR and RVR in previously treated non-responders
Rapid virological response was achieved in 37 of 49 (76 %) older patients. SVR rates were significantly higher for RVR than in non-RVR in patients with both ss469415590 TT/TT (96 vs. 50 %, P = 0.003) and TT/DG or DG/DG (64 vs. 0 %, P = 0.011) genotypes (Fig. 2b) . No older patient with ss469415590 TT/DG or DG/DG who was non-RVR achieved SVR.
Adverse events TVR and PEG-IFN/RBV combination treatment is associated with a high frequency of adverse events such as anemia and renal dysfunction [10] [11] [12] [13] [14] . Pre-treatment hemoglobin levels were significantly lower in older patients than younger patients, and serum creatinine levels Categorical data are represented as numbers of patients, and continuous data are represented as median and range.
SVR sustained virological response, NR non-responder, TVR telaprevir, HCV hepatitis C virus, Core70 HCV core protein amino acid 70
were significantly higher (Table 1) . Similarly, treatmentrelated decreases in hemoglobin levels (Fig. 3a) and increases in serum creatinine levels (Fig. 3b) were higher in older patients compared to younger patients. These adverse events resulted in a significantly higher frequency of discontinuation of the treatment in older patients (33 vs. 16 %, P = 0.008) (Fig. 3c) . The total average dosages of TVR and PEG-IFNa2b during the treatment were based on body weight and tended to be larger in younger patients than older patients (2,286.5 ± 68.8 vs. 2,076.6 ± 99.0 mg/kg and 31.1 ± 1.1 vs. 28.0 ± 1.5 lg/kg, respectively); those of RBV were significantly larger in younger patients than older patients (1,068.0 ± 37.9 vs. 903.6 ± 88.8 mg/kg, P = 0.004). The difference of the total dosages of agents may be one of the contributing factors for the higher SVR rate in younger patients compared to older patients.
Effect of initial TVR dose on adverse events and treatment response in older patients 33 out of 87 (38 %) older patients were treated with an initial TVR dose of 2,250 mg, and the remaining 54 patients (62 %) were administered a reduced initial dose of 1,500 mg (Table 1 ). The average dosage of total TVR based on body weight was significantly larger in patients treated with an initial TVR dose of 2,250 mg than patients with an initial TVR dose of 1,500 mg (P = 0.006) (Fig. 4a) . Both the decrease of hemoglobin levels (Fig. 4b ) and the increase of creatinine levels (Fig. 4c) in older patients treated with the 1,500 mg TVR dose were smaller than in patients who received the 2,250 mg dose. However, initial TVR dose was not associated with the rate of SVR (Fig. 4d) . The oldest patient in this study, an 80-year-old male, was treated with the reduced initial dose of TVR. The patient was able to complete the 24-week treatment and achieved SVR.
Discussion
Elimination of HCV after IFN therapy significantly reduces the risk of hepatocellular carcinoma (HCC) and death in older patients [30] ; however, the best way to treat older patients with genotype 1 HCV infection is controversial because of the lower viral response rate and higher frequency of adverse events in this group [7, 31, 32] . In fact, this study also showed that adverse events such as anemia and renal dysfunction were more serious (Fig. 3a, b) and SVR rate was significantly lower (Fig. 1) in older patients than in younger patients.
In this study, SVR rates were higher in treatment-naïve patients and prior relapsers than prior non-responders in both younger and older patients (Fig. 1) . This suggests that treatment-naïve patients and prior treatment relapsers are suitable candidates for triple therapy regardless of age.
SNP ss469415590 in the IFNL4 gene is strongly associated with HCV clearance through both the innate immune reaction and by PEG-IFN plus ribavirin therapy [22] . IFNL4 genotype is also an important predictor of the probability of eradicating the virus by triple therapy. While the SVR rate of older patients with IFNL4 genotype TT/TT was 82 %, the eradication rate was 56 %, even in older patients with non-response to prior therapy ( Fig. 2A) . In contrast, patients with IFNL4 TT/DG or DG/DG, especially among non-responders to prior therapy, had poor response. Therefore, older patients who have IFNL4 genotype TT/TT should be treated by triple therapy. Older patients with IFNL4 genotype TT/DG or DG/DG are expected to have poor response to the therapy.
IFNL4 SNP ss469415590 is in strong linkage disequilibrium with IL28B SNP rs8099917, especially in Asians [22] . In this study, only 4 out of 313 patients (1.3 %) showed discrepant haplotypes. Further analysis with many more patients is needed to determine whether rs8099917 or ss469415590 is more important for prediction of the treatment response. However, to a large extent the polymorphisms provide equivalent information, and patients who have already been genotyped for rs8099917 would probably not benefit from genotyping for ss469415590.
It is important to predict the effect of the therapy as early as possible in older patients.
In this study, the rapid change in HCV RNA levels early in treatment is an important predictor of treatment success. More than 85 % of patients who achieved RVR also achieved SVR. In contrast, patients who did not achieve RVR showed poor response to the therapy, especially in patients with IFNL4 TT/DG or DG/DG genotypes (Fig. 2b) . Accordingly, termination of the therapy should be considered when older patients with IFNL4 genotypes associated with poor response fail to show RVR.
The dose of TVR for use in triple therapy was determined based on a dose-finding study conducted in the United States and Europe, which found that the 2,250 mg regimen achieved the greatest reduction of HCV RNA [33] . However, average body weights of Japanese patients are lower than American and European patients. It was reported that the anti-HCV effect of triple therapy was similar when patients were given TVR at 1,500 mg/day compared with those given at 2,250 mg/ day in the Japanese patients [34] . In the present study, dose reduction of the initial TVR dose alleviated adverse events such anemia and renal dysfunction (Fig. 4b, c) without affecting the virological response rate in older patients (Fig. 4d) , suggesting that reduction of TVR might be possible for older patients.
In conclusion, older patients who received triple therapy with TVR and PEG-IFN/RBV showed a lower viral response than younger patients. Analysis of IFNL4 polymorphism is a valuable predictor in older patients receiving telaprevir triple therapy. TVR dose reduction could alleviate adverse events without compromising the treatment response in older patients.
